By Drug Target Review2025-04-14T08:30:18
From law to biotech, Brian Finrow's career path has been anything but conventional. As Co-founder and CEO of Lumen Bioscience, he’s steering the company’s innovative approach to drug discovery, focusing on preventative biologics that offer scalable, cost-effective solutions. Find out how Finrow's unique spirulina-based platform is changing the way we ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2023-07-04T09:00:08
Sponsored by SB Drug Discovery
2023-02-02T11:05:15
Sponsored by Cell Signaling Technology
2023-01-06T16:37:30
Sponsored by Catalent
2023-03-23T14:46:21
Sponsored by Bio-Techne
2025-05-08T10:38:52
Sponsored by Takara Bio USA
Site powered by Webvision Cloud